Meeting Banner
Abstract #1210

Assessing lung perfusion in pulmonary hypertension

Paul J.C. Hughes1, Andrew J. Swift1,2, Frederick J. Wilson3, Marcella Cogliano1, Fasial AA Alandejani1, Anthony Cahn3, Lindsay Kendall3, David G. Kiely2,4,5, and Jim M. Wild1,2
1POLARIS, Department of Infection, Immunity and Cardiovascular Disease, The University of Sheffield, Sheffield, United Kingdom, 2Insigneo Institute for in silico Medicine, The University of Sheffield, Sheffield, United Kingdom, 3GlaxoSmithKline R&D Ltd, Stevenage, United Kingdom, 4Sheffield Pulmonary Vascular Disease, Sheffield Teaching Hospitals NHS Trust, Sheffield, United Kingdom, 5Department of Infection, Immunity and Cardiovascular Disease, The University of Sheffield, Sheffield, United Kingdom

Pulmonary arterial hypertension (PAH) is a condition that impacts on lug perfusion and right ventricular function. This work aimed to assess i) the diagnostic utility of relative pulmonary perfusion parameters to distinguish patients with PAH from healthy controls and ii) changes in lung perfusion in 2 patient groups with PAH: newly diagnosed patients initiating and patients escalating treatment and clinically stable patients who had no escalation of treatment.

This abstract and the presentation materials are available to 2020 meeting attendees and eLibrary customers only; a login is required.

Join Here